Loading...
Filament Health Corp.
FH.NE•NEO
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.01
CA$-0.00(-33.33%)

Over the past four quarters, Filament Health Corp. demonstrated steady revenue growth, increasing from $1.73M in Q4 2023 to $19021.00 in Q3 2024. Operating income reached $0.00 in Q3 2024, maintaining a consistent N/A margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$914197.00, reflecting operational efficiency. Net income rose to -$976419.00, with EPS at -$0.004. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan